<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00836654</url>
  </required_header>
  <id_info>
    <org_study_id>60117</org_study_id>
    <nct_id>NCT00836654</nct_id>
  </id_info>
  <brief_title>Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group</brief_title>
  <official_title>Two-Arm, Randomized (2:1), Open-Label Phase II/III Study in EpCAM Positive Cancer Patients With Symptomatic Malignant Ascites Using the Trifuncitonal Bispecific Antibody Removab (Anti-EpCAM x Anti-CD3) Versus an Untreated Control Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neovii Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neovii Biotech</source>
  <brief_summary>
    <textblock>
      The study will be performed to obtain further efficacy and safety data in order to obtain a
      marketing authorization (pivotal study). In addition, health economic data are to be
      collected.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">258</enrollment>
  <condition>EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast)</condition>
  <condition>Malignant Ascites</condition>
  <arm_group>
    <arm_group_label>1 Catumaxomab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient received Catumaxomab and paracentesis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2:</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patient treated by paracentesis alone, but after the second paracentesis the patient is able to cross-over in the Catumaxomab-arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Catumaxomab (Removab)</intervention_name>
    <description>Puncture free survival</description>
    <arm_group_label>1 Catumaxomab</arm_group_label>
    <other_name>Removab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>paracentesis</intervention_name>
    <arm_group_label>1 Catumaxomab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histological confirmed diagnosis cancer

          -  symptomatic malignant ascites

          -  EpCAM positive tumor

          -  EOCG 0-2

          -  negative pregnancy

        Exclusion Criteria:

          -  acute or chronic infection

          -  exposure to investigational product, cancer chemo- or radiotherapy within the last 28
             days

          -  previous treatment with mouse monoclonal antibodies

          -  known or suspected hypersensitivity to Removab or similar antibodies

          -  inadequate renal function

          -  inadequate hepatic function (AST, ALt, GTP,&lt; x ULN; bilirubin &lt;1.5xULN)

          -  Platelets &gt; 80000 cells/mm3; absolute neutrophil count (ANC) &lt; 1500 cells/mm3

          -  BMI &lt; 17

          -  Patients with reduced nutritional status

          -  Ileus within the last 30 days

          -  Brain metastases in cancer history

          -  Pregnant and nursing women

          -  history of myocardial infarction, congestive heart failure or relevant cardiac
             arrhythmia within previous 3 months

          -  inadequate respiratory function in option of investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood. 2001 Oct 15;98(8):2526-34.</citation>
    <PMID>11588051</PMID>
  </reference>
  <reference>
    <citation>Riesenberg R, Buchner A, Pohla H, Lindhofer H. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3). J Histochem Cytochem. 2001 Jul;49(7):911-7.</citation>
    <PMID>11410615</PMID>
  </reference>
  <reference>
    <citation>Zeidler R, Mysliwietz J, Csánady M, Walz A, Ziegler I, Schmitt B, Wollenberg B, Lindhofer H. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer. 2000 Jul;83(2):261-6.</citation>
    <PMID>10901380</PMID>
  </reference>
  <reference>
    <citation>Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, Lindhofer H. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol. 1999 Aug 1;163(3):1246-52.</citation>
    <PMID>10415020</PMID>
  </reference>
  <reference>
    <citation>Heiss MM, Ströhlein MA, Jäger M, Kimmig R, Burges A, Schoberth A, Jauch KW, Schildberg FW, Lindhofer H. Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer. 2005 Nov 10;117(3):435-43.</citation>
    <PMID>15906359</PMID>
  </reference>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2009</study_first_submitted>
  <study_first_submitted_qc>February 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2009</study_first_posted>
  <last_update_submitted>February 4, 2009</last_update_submitted>
  <last_update_submitted_qc>February 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2009</last_update_posted>
  <keyword>EpCAM positive tumor</keyword>
  <keyword>malignant ascites</keyword>
  <keyword>intraperitoneal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Bispecific</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

